CERo Therapeutics Holdings Inc
CERO
Company Profile
Business description
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.
Contact
201 Haskings Way
Suite 230
South San FranciscoCA94080
USAT: +1 650 407-2376
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
8
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,826.70 | 48.80 | 0.56% |
| CAC 40 | 7,902.25 | 23.79 | 0.30% |
| DAX 40 | 24,456.81 | 92.75 | -0.38% |
| Dow JONES (US) | 44,758.66 | 300.36 | 0.68% |
| FTSE 100 | 8,975.66 | 108.64 | 1.23% |
| HKSE | 24,028.37 | 136.05 | 0.57% |
| NASDAQ | 20,641.29 | 29.95 | 0.15% |
| Nikkei 225 | 39,646.36 | 174.92 | -0.44% |
| NZX 50 Index | 12,760.20 | 8.41 | -0.07% |
| S&P 500 | 6,287.71 | 24.45 | 0.39% |
| S&P/ASX 200 | 8,589.20 | 50.60 | 0.59% |
| SSE Composite Index | 3,509.68 | 16.63 | 0.48% |